Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Wednesday, December 2, 2020

Inhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma

xloma.fota13 shared this article with you from Inoreader
Inhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma

Inhibition of the activin receptor signaling pathway reduces tumor volume, pathological bone remodeling, and counteracts the cachexia that follows in the wake of osteosarcoma.


Abstract

Osteosarcoma is a cancer of pathological bone remodeling with high mortality and severe comorbidity. New therapies are urgently needed. Activin A, a member of the transforming growth factor β (TGFβ) superfamily, has been suggested to stimulate proliferation and invasion of osteosarcoma cells in vitro, thus representing a potential therapeutic target. In this study, inhibition of the activin receptor signaling pathway was explored as a therapy for osteosarcoma. In a murine intratibial osteosarcoma xenograft model, two types of inhibitors were tested: (a) a soluble activin type IIA decoy receptor (ActRIIA‐mFc), or (b) a modified variant of follistatin (FSTΔHBS‐hFc), either alone or in combination with a bisphosphonate. Both inhibitors reduced primary tumor development by nearly 50% compared to vehicle treatment. When ActRIIA‐mFc was combined with bisphosphonate, the effect on tumor size became even more pronounced (78% reduction vs. vehicle). Moreover, FSTΔ HBS‐hFc increased body weight in the face of tumor progression (14% increase vs. vehicle), and ActRIIA‐mFc reduced the number of lung metastases when combined with bisphosphonate. The present study demonstrates a novel approach to treating osteosarcoma and encourages further investigation of inhibition of the activin receptor signaling pathway as an intervention against the disease.

View on the web

No comments:

Post a Comment